secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0001193125-23-260785
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.01, 2.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics closes acquisition of EryDel for up to $485M in milestones
------------------------------------------------------------------------------

- Issued 6,525,315 shares (15.2% ownership) to EryDel shareholders; up to 725,036 more shares at first anniversary.
- Contingent payments up to $485M: $5M development, $25M NDA acceptance, $60M approval, $395M sales milestones.
- Guarantees EryDel's EUR 30M EIB facility; ~EUR 10M drawn, maturity Aug 2026, fixed 9% interest.
- Appointed Luca Benatti as Class II director; granted option for 54,000 shares vesting over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523260785/0001193125-23-260785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523260785/d562811d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-260785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer